Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Cyclin-dependent kinase pathways as targets for women's cancer treatment

Gottfried E Konecny1

  • 1David Geffen School of Medicine, University of California, Los Angeles, California, USA.

Current Opinion in Obstetrics & Gynecology
|December 8, 2015
PubMed
Abstract

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors show promise in treating various cancers, including breast cancer and melanoma. Further research is ongoing to explore their efficacy in other tumor types and overcome resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) regulate cell cycle progression.
  • CDK 4/6 inhibitors represent a novel therapeutic class targeting cell cycle transition.
  • Targeting CDKs is a significant focus in cancer research.

Purpose of the Study:

  • To review preclinical and clinical studies of CDK 4/6 inhibitors in various cancers.
  • To examine preclinical data for future development directions in glioblastoma, renal, and ovarian cancers.

Main Methods:

  • Review of preclinical and clinical studies on CDK 4/6 inhibitors.
  • Analysis of proposed biomarkers for response, including cyclin D, CDKN2A (p16), and CDK4.
  • Investigation of novel therapeutic agents like palbociclib, abemaciclib, and ribociclib.

Main Results:

  • Palbociclib, abemaciclib, and ribociclib demonstrate clinical activity in breast cancer, liposarcoma, mantel cell lymphoma, and melanoma.
  • These oral CDK 4/6 inhibitors are associated with minimal toxicity.
  • Biomarkers such as cyclin D overexpression and CDKN2A loss correlate with response.

Conclusions:

  • CDK 4/6 inhibitors exhibit significant promise in multiple cancer types.
  • Preclinical data suggest potential for glioblastoma, renal, and ovarian cancer treatment.
  • Further research is essential to understand resistance and develop combination therapies.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.5K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.1K